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Introduction
Magnetic resonance imaging (MRI) is being used 
 increasingly in the diagnosis of prostate cancer (PC). 
Over the past years, the prostate MRI scan protocol that 
is recommended by the international guidelines has been 
changing and also the clinical indications for performing a 
prostate MRI have evolved. In this paper, the  currently con-
sidered optimal prostate MRI scan protocol is described, 
and the accuracy of prostate MRI in the  diagnosis of 
 clinically significant PC in patients with elevated prostate 
specific antigen (PSA) is reviewed.
Prostate MRI Scan Protocol
Morphological T2-Weighted Imaging (T2-WI) is the basis 
of any prostate MRI exam. Large and high-grade PC in the 
prostate can be identified as ill-defined low signal  intensity 
(SI) lesions, contrasting well with the high background SI 
of the peripheral zone (PZ), but are often more difficult 
to distinguish in the transition zone (TZ) due to the lower 
and more heterogeneous background SI of the latter 
caused by sparser glandular tissue and the more promi-
nent fibromuscular tissue [1, 2]. The high and very high 
SI of what is commonly denoted as normal prostate tissue 
basically represents cystic atrophy and large-gland simple 
atrophy [3–5] whereas pure normal prostate glands are 
actually iso-intense on T2-WI. This explains why the PZ is 
iso-intense on T2-WI in young patients [6–8].
T2-WI alone is however not sufficient to detect smaller 
and less aggressive PC and to improve the diagnostic 
accuracy of prostate MRI, it is necessary to add T1-WI (to 
detect post-biopsy haemorrhage) and functional imag-
ing  techniques. In 2011 the ESUR (European Society of 
Urogenital Radiology) published guidelines on prostate 
MRI [3], describing the minimal requirements for a high 
quality prostate MRI. A multiparametric MRI (mpMRI) 
approach was promoted, defined as a scan protocol com-
bining morphological T2-WI with at least two functional 
imaging techniques, such as dynamic contrast-enhanced 
MRI (DCE-MRI), diffusion-weighted imaging (DWI) 
and/or MR spectroscopy (MRSI). A mpMRI provided 
an abundance of information about anatomy, tissue 
 density,  neovascularity, vascular permeability, metabolite 
 concentrations, mobility of water molecules, etc … and 
it was thought that the more information one achieved, 
the better differentiation would be possible between PC 
and non-cancerous tissue. Some histological conditions 
indeed have unique features on mpMRI and are conse-
quently easy to recognize. Cystic atrophy is such a condi-
tion: it shows very high SI on T2-WI surrounded by a thin 
hypo-intense line, bulging on the surrounding tissues, 
absent contrast enhancement on DCE, high ADC value 
on DWI and high citrate concentrations on MRSI. Poorly 
differentiated PC also has typical features: very low SI 
on T2-WI, (very) low ADC value on DWI, strong contrast 
enhancement on DCE and high choline concentrations on 
MRSI [5]. The interpretation of mpMRI may however be 
difficult because non-cancerous conditions such as aden-
osis, post-atrophic hyperplasia (PAH) and inflammation 
may mimic well-differentiated PC. These conditions all 
show ill-defined iso- to hypointense SI on T2-WI, moderate 
ADC values on DWI, moderate to strong contrast enhance-
ment on DCE and moderate citrate and choline concen-
trations on MRSI. Despite the abundance of information 
provided by the different morphological and functional 
imaging sequences, a mpMRI protocol may thus not avoid 
that benign mimickers cause false positive results or that 
PC are missed. Moreover, mpMRI has the disadvantage of 
additional costs (e.g. Gadolinium contrast has to be pur-
chased) and the need for more experienced readers (it may 
be difficult to draw the right conclusion from the interpre-
tation of all the different sequences that sometimes show 
conflicting results). Another disadvantage of mpMRI is the 
long scanning time of about 45 minutes. This becomes 
a problem as urologists are increasingly convinced about 
the usefulness of prostate MRI and the number of requests 
for imaging is growing. To further increase the adoption of 
prostate MRI by urologists and radiologists while avoiding 
long waiting lists, it was necessary to modify mpMRI into 
a scan protocol that was quick and simple.
Therefore, since 2015 attempts have been made to 
reduce the number of scan sequences. The ESUR and 
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American College of Radiology (ACR) published a second 
version of the prostate MRI guidelines [9] and in these new 
guidelines, the role of DCE in the interpretation of pros-
tate MRI is reduced (although it is still recommended to be 
scanned as part of a mpMRI) and MRSI is no longer recom-
mended. Omitting MRSI and DCE considerably shortens 
the prostate MRI examination time and reduces costs [10].
In recent years the quality of the DWI sequences on 
the newest MRI equipment have improved impressively 
and recent literature data show that DCE has currently 
limited added value over T2-WI and DWI [11–15]. Even 
an  ultrashort scan protocol limited to only transverse 
T2-WI and DWI showed similar diagnostic performance 
as mpMRI for the detection of clinically significant PC, 
but with the advantage of reducing scan time with about 
15 minutes (from about 25 minutes to 10 minutes) [16].
Currently, a scan protocol consisting of only T2-WI 
 (preferably multiplanar) and DWI seems to be the best 
combination as a short standard protocol in daily routine 
for performing prostate MRI within a short time frame 
(about 20 minutes) and offering high sensitivity for detec-
tion of aggressive PC in patients with elevated PSA. The 
addition of DCE and/or MRSI may be preserved for other 
clinical indications, such as detection of PC recurrence 
after treatment (radiation therapy, radical prostatectomy, 
brachytherapy, HIFU …) or in doubtful or in complicated 
cases (e.g. patients with a previous indeterminate MRI, or 
patients with continuously rising PSA despite negative MRI 
findings). The decision which scan sequences are needed 
should be made by the radiologist and may be determined 
before the examination based on the  clinical question and 
the information provided by the  referring clinician, or may 
be delayed to after completion of the T2-WI and DWI, based 
on their image quality and  diagnostic interpretation.
In the radiological community the debate is still ongo-
ing about the need of using an endorectal coil and/or the 
required magnetic field strength that is necessary for per-
forming high quality prostate MRI. It is generally accepted 
that both 1.5 Tesla and 3.0 Tesla scanners can provide ade-
quate and reliable diagnostic quality when the acquisition 
parameters are optimized and appropriate technology is 
employed [9].
The use of an endorectal coil likely also improves the 
diagnostic performance at 3.0 Tesla [17, 18] but Barth et al. 
showed that the image quality of T2-WI was comparable to 
3.0 Tesla without endorectal coil and that the  endorectal 
coil insertion caused low to moderate discomfort and pain 
to the patients, which were arguments for omission of the 
endorectal coil at 3.0 Tesla [19]. Anyhow, Bratan et al. [20] 
showed that PC detection rates are not significantly influ-
enced by field strength nor coils used for imaging, but 
more importantly by PC characteristics such as tumour 
volume, Gleason score, architecture and location.
Diagnostic Accuracy of Prostate MRI in the 
Diagnosis of PC
The determination of the diagnostic accuracy of prostate 
MRI is dependent on the histopathological gold stand-
ard that is used as a reference and on the threshold for a 
 positive MRI that is applied when interpreting the images.
The histopathological gold standard has changed over 
the years. In the past, urologists aimed at detecting and 
treating any PC of any size and any Gleason score, but 
since the turn of the century, it became obvious that this 
resulted in over-diagnosis and overtreatment of indolent 
PC. As a consequence, the concept of clinically signifi-
cant PC was introduced, referring to the proportion of PC 
that are deemed aggressive and need treatment, and the 
notion of insignificant PC referring to the proportion of PC 
that are unlikely to progress to biologic significance and 
in which active surveillance may be offered as treatment 
option. There is, however, currently still lack of consen-
sus among urologists and pathologists about what exactly 
constitutes a clinically insignificant PC and therefore the 
true diagnostic accuracy of prostate MRI remains difficult 
to determine [21].
The threshold for scoring prostate MRI positive or 
 negative may also influence the accuracy in the  detection 
of clinically significant PC. The reported prostate MRI 
 conclusion is not always straightforward (completely 
 normal versus very suspicious) because doubtful findings or 
conflicting results between the different imaging modali-
ties may occur. The 5-point Prostate Imaging Reporting 
and Data System (PI-RADS) scoring system, introduced 
in the prostate MRI guidelines of 2011 [3, 9, 22] entails 
assignment of separate scores for each of the scanned 
MRI sequences and provides explicit verbal descriptions 
on how to generate them. Each exam is assigned with an 
overall assessment score ranging from 1 (indicating that 
clinically significant PC is highly unlikely to be present) to 
5 (indicating that clinically significant PC is highly likely 
to be present). An overall assessment score of 3 indicates 
equivocal findings and this enables the radiologist to com-
municate doubtful findings to the referring clinician. The 
application of an equivocal score 3 increases the specificity 
of findings classified as 1, 2, 4 or 5 but it may be a source 
of confusion to clinicians [21, 23] because this indetermi-
nate prostate MRI result often needs to be translated into 
a binary clinical decision, i.e. to biopsy or not, in patients 
with elevated PSA. The recommendation to biopsy then 
depends on whether an overall assessment score of 3 or 4 
is used as threshold for a  positive MRI [24, 25].
The PC volume and Gleason score highly influence the 
detectability on prostate MRI with larger tumours being 
detected more easily than smaller ones [20, 26, 27]. Very 
small tumours <1 mm diameter are below the  detection 
limit of MRI but a PC of 1 cm diameter (0.5 ml) is well 
within the spatial resolution of T2-WI [20, 26–29]. Higher 
grade PC are histologically associated with more pro-
nounced destruction of the normal glands, more solid 
areas of tumour cells and less fluid content as compared 
to lower grade PC, and consequently show a higher 
 detectability on MRI [20, 26–28].
The true strength of prostate MRI lies not in the 
 detection of any PC including very small or low-grade 
lesions, but in the detection or exclusion of the aggressive 
tumours.
The reported detection rates of prostate MRI range from 
100% for Gleason ≥8 PC with size >2.0 ml to 21–29% 
for Gleason 6 PC measuring <0.5 ml [20, 26, 27]. The 
De Visschere: Improving the Diagnosis of Clinically Significant Prostate Cancer with 
Magnetic Resonance Imaging
Art. 22, pp.  3 of 8 
reported sensitivities and specificities of prostate MRI 
are 80–90% and 47–61% respectively, for detection of 
high-grade PC and 71–84% and 33–70%, respectively, 
for detection of PC of any grade [11, 15, 30–42]. Negative 
predictive  values of 92–100% are reported for clinically 
significant PC and 63–91% for PC of any grade [11, 30–36, 
43–48]. An  analysis of PC that were missed on mpMRI [49] 
showed that 67.7% of the missed PC were low grade and 
96.6% were organ-confined. With a multiparametric scan 
 protocol, the detection rates for clinically significant PC in 
biopsy-naive males and men with prior negative biopsies, 
widely range from 44% to 87% and negative predictive 
values ranging from 63% to 98%, with trends depending 
mainly on the definition of clinically significant PC that 
was applied [46]. A short prostate MRI scan protocol con-
sisting of only T2-WI and DWI seems not to show inferior 
diagnostic accuracy as compared to mpMRI [16].
In summary, although there is a high variability between 
the reported accuracies due to differences in definition of 
the histopathological reference and threshold for a posi-
tive MRI that are used, in general the detection rate of 
prostate MRI for any PC is rather moderate, whereas the 
detection and exclusion of high grade and large volume 
PC is very high to excellent.
Clinical Role of MRI in the Detection of PC
The clinical role of prostate MRI has evolved in the last 
decade. In the past, prostate MRI was mainly used to visu-
alize biopsy-proven PC for staging purposes to inform the 
surgeon before radical prostatectomy, about the extent of 
the disease or to help the radiation oncologist to  delineate 
the clinical target volume [1, 2]. The ability of prostate 
MRI to detect high grade and large volume PC may help 
to discriminate clinically significant PC from indolent or 
absent cancer before the biopsy which has led to a refined 
diagnostic pathway [50]. Prostate MRI may improve the 
diagnosis of clinically significant PC by serving as an addi-
tional decision tool to triage patients with elevated PSA 
towards immediate biopsy or not. When a suspicious 
lesion is demonstrated on pre-biopsy prostate MRI, the 
likelihood of a high-grade PC is high and consequently 
a targeted biopsy to the suspicious lesion may be per-
formed (Figure 1). When the imaging findings are normal 
on pre-biopsy prostate MRI, the risk of a high-grade PC is 
very low (Figure 2). Since the growth and stage progres-
sion of PC tend to be slow, consideration could reasonably 
be given to deferring or even omitting the biopsy in these 
patients although continued monitoring with repetitive 
PSA sampling, DRE and/or MRI remains necessary [25, 43, 
44, 51–55].
Currently the implementation of prostate MRI in the 
international guidelines is limited.
The EAU (European Association of Urology) and NCCN 
(National Comprehensive Cancer Network) guidelines 
recommend prostate mpMRI only before repeat biopsy, 
when clinical suspicion of PC persists in spite of initial 
negative biopsies [3, 43, 56–59]. However, the argu-
ments for performing prostate MRI before initial biopsy 
become stronger. It has been shown that the implemen-
tation of pre-biopsy MRI (with consequently targeted 
MR-guided biopsy in case of a positive MRI or no biopsy in 
case of a negative MRI) in men with elevated PSA results 
Figure 1: 60-year-old men with elevated PSA (20 ng/ml). On axial T2-weighted image (A) A nodular lesion with low 
SI is noted (white circle) posteriorly in de peripheral zone of the mid prostate. This nodule shows low ADC value (B) 
and High SI on high-b-value image (C) of DWI, and strong Gadolinium contrast enhancement (D), suspicious for a 
high-grade prostate cancer, PI-RADS overall assessment score 5. A targeted transrectal ultrasound guided biopsy was 
performed, confirming a Gleason 4 + 4 prostate cancer.
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in an equal to slightly higher detection rate of clini-
cally significant PC, 25–30% reduction in the number 
of men biopsied, and 10% fewer men being attributed 
the diagnosis of clinically insignificant PC [24, 60–62]. 
Two randomized controlled trials on the use of mpMRI 
in biopsy naive patients showed conflicting results [63, 
64] but multicentre controlled studies are pending, such 
as the PRECISION trial (international study in which 
Ghent University Hospital participates) and the MRI-
FIRST trial. These studies are mainly performed in aca-
demic centres with radiological expertise but a problem 
is that worse results are observed in centres with limited 
experience [65]. Tonttila et al. [61] performed a prospec-
tive randomized controlled trial concluding that mpMRI 
before biopsy did not improve PC detection rates but the 
mpMRI were not scanned or reported according to the 
PI-RADS standards and the urologist who performed the 
targeted biopsies was unexperienced and used a cogni-
tive approach. Branger et al. [48] reported that a nega-
tive MRI is no warrantor for absence of significant cancer 
but most of the MRIs were done externally in differing 
hospitals or private practices with limited experience. 
This variation in image quality and radiologist’s perfor-
mance in examination interpretation is an important 
barrier to the implementation of prostate MRI in the 
guidelines [65].
Conclusions
The prostate MRI scan protocol has been changing over 
the years. With the currently available techniques, a short 
scan protocol consisting of only T2-WI and DWI seems 
to offer sufficient information and accuracy for most 
 diagnostic indications. Only in doubtful or complicated 
cases, DCE or MRSI may be performed additionally.
The accuracy of prostate MRI to detect clinically 
significant PC varies with the applied definition of clinically 
significant disease. The major value of prostate MRI is to 
selectively demonstrate or exclude high grade and large 
tumours. Prostate MRI offers additional information, next 
to clinical biomarkers such as PSA level and digital rectal 
examination, to determine the likelihood of a clinically 
significant PC. Prostate MRI may improve the diagnosis 
of clinically significant PC by serving as an additional 
decision tool to triage patients with elevated PSA towards 
immediate biopsy or not.
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